treprostinil / Generic mfg. - LARVOL DELTA

Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis. (PubMed, J Cardiovasc Dev Dis) - "Of the 15 patients intolerant to nebulized treprostinil who were transitioned to a dry powder inhaler, the majority (87%) were able to tolerate the other formulation. The medication was well-tolerated with a large percentage of patients remaining on therapy indefinitely and reaching the targeted therapeutic dose."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Hypertension • Interstitial Lung Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Parenteral treprostinil in paediatric pulmonary arterial hypertension: a systematic review and meta-analysis. (PubMed, Eur Respir Rev) - "Based on currently available published data, parenteral treprostinil is effective and safe in the treatment of paediatric PAH."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension • Pediatrics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases (PubMed, Z Rheumatol) - "Promising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future."

Journal • Review • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology

Marked clinical and haemodynamic improvement with sotatercept in severe refractory pulmonary arterial hypertension associated with corrected complex congenital heart disease. (PubMed, Respir Med Case Rep) - "Despite treatment with tadalafil, ambrisentan, and high dose subcutaneous treprostinil, she remained at intermediate-high risk, with WHO-FC III, NT-proBNP 3773 pg/mL and a 6-min walk distance (6MWD) of 480 m. Sotatercept was initiated through an expanded access program. A significant and rapid improvement in haemodynamics and functional capacity was observed after starting sotatercept, in a patient with severe PAH-CHD refractory to maximal therapy. Sotatercept may represent an effective rescue therapy and a potential therapeutic option for complex and severe PAH patients."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Open Label Treprostinil Raynaud's Study (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Rheumatology

Outcome of Pediatric Pulmonary Hypertension Patients Requiring ECMO (SCCM 2026) - "100% (31/31) of patients received at least one PAH therapy prior to and during ECMO [31/31 (100%) inhaled nitric oxide or inhaled epoprostenol; 26/31 (84%) sildenafil, tadalafil or riociugat; 18/31 (58%) macitentan, ambrisentan or bosentan; 8/31(26%) selexipag; 10/31(32%) treprostinil. Pediatric PAH is a complex disease due to varied etiologies often requiring multiple medications to effectively manage. Certain subpopulations such as those with single ventricle CHD have higher mortality especially when requiring ECMO. Further study is necessary to determine if earlier identification and management of PAH patients prior to ECMO can improve survival and decrease need for mechanical circulatory support in this high-risk population."

Clinical • Cardiovascular • Heart Failure • Hematological Disorders • Infectious Disease • Pediatrics • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Acute Pulmonary Embolism Complicated by Bidirectional Atrial Septal Defect (SCCM 2026) - "As such, patient became hypoxic refractory to maximal ventilatory support, subsequently was started on intravenous treprostinil, and was placed on Veno-arterial Extra Corporeal Membrane Oxygenation (VA-ECMO)...Optimizing pulmonary hypertension management may not consistently improve arterial oxygen saturation, and decisions regarding ECMO weaning should be based on the overall clinical picture rather than laboratory values alone. These patients live with chronic hypoxemia and may demonstrate a higher tolerance to low oxygen levels."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

The Rising Cost of ICU Drugs (SCCM 2026) - "The top six most expensive ICU drugs based on average monthly cost were albumin, vasopressin, propofol, dexmedetomidine, treprostinil, and amphotericin-B liposome. The overall inpatient drug cost, ICU drug cost, and ICU drug cost per ICU patient day rose by 51%, 43%, and 55% respectively from FY 2012 - 2023. The overall inpatient drug cost, ICU drug cost, and ICU drug cost per ICU patient day rose by 51%, 43%, and 55% respectively from FY 2012 - 2023. Despite these increases, the percentage of ICU drug cost relative the overall inpatient drug cost trended downward in the same period. This suggests that the increase in cost of non-ICU drugs outpaced that of ICU drugs to an extent that resulted in a net decrease in the percentage of ICU drug cost."

Mood Disorders

VOLATILE ORGANIC COMPOUND EXPOSURE, SCLERODERMA-SPECTRUM AUTOIMMUNITY, AND PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "He was started on sildenafil, inhaled treprostinil, diuretics, and rate control. In unexplained PAH with autoimmune serologies, environmental history can expedite diagnosis of SSc-spectrum PAH and allow early targeted therapy."

Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Respiratory Diseases • Scleroderma • Systemic Sclerosis

SEVERE PULMONARY ARTERIAL HYPERTENSION AS THE INITIAL MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS/MIXED CONNECTIVE TISSUE DISEASE OVERLAP SYNDROME (ACC 2026) - "Decision-Making: She was treated with inotropic support, intravenous steroids, immunosuppressants and treprostinil...She was maintained on tadalafil, selexipag, rituximab and mycophenolate. PAH can be a manifestation of uncontrolled SLE/MCTD, with notable improvement after treating the flare. Early diagnosis, multidisciplinary approach and multi-modal therapy are key to controlling flares, managing PAH and improving outcomes."

Cardiovascular • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus

CARDIOGENIC SHOCK DUE TO GROUP 1 PULMONARY HYPERTENSION IN A PATIENT ON BORTEZOMIB AND WITH SUBCLINICAL SJOGREN SYNDROME (ACC 2026) - "Decision-Making: Epoprostenol was started, pressors weaned, and eventually transitioned to treprostinil and sildenafil. Group 1 PAH leading to cardiogenic shock can be induced by bortezomib with underlying connective tissue disease and may be reversible upon stopping bortezomib with PH therapy."

Clinical • Cardiovascular • Hematological Malignancies • Hypertension • Immunology • Multiple Myeloma • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Sjogren's Syndrome

EARLY AND HIGH-DOSE TREPROSTINIL THERAPY TARGETING PRESSURE TO IMPROVE RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: ARTISAN INTERIM ANALYSIS (ACC 2026) - P4 | "Early high-dose treprostinil therapy targeting reduced afterload demonstrates significant RV functional improvement and cardiac reverse remodeling at 12 months. Sponsored by United Therapeutics."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

THROMBOCYTOPENIA ASSOCIATED THYROID HEMATOMA FOLLOWING WINREVAIR THERAPY (ACC 2026) - "Background: Winrevair (sotatercept-cskr), approved in 2024 for pulmonary arterial hypertension (PAH, WHO Group 1), is an activin signaling inhibitor that enhances exercise capacity and slows disease progression...Case: A 41-year-old patient with PAH, previously treated with treprostinil, riociguat, and macitentan, started Winrevair... This case underscores the risk of severe thrombocytopenia with Winrevair, leading to a thyroid hematoma post-biopsy. Vigilant platelet monitoring, stricter pre-procedure thresholds, and dose adjustments are critical to prevent complications in PAH patients."

Cardiovascular • Endocrine Disorders • Hematological Disorders • Pulmonary Arterial Hypertension • Respiratory Diseases • Thrombocytopenia

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. (PubMed, N Engl J Med) - P3 | "In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.)."

Journal • Cough • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Dupixent as a Treatment for Type 1 Hypersensitivity Reactions to Subcutaneous Treprostinil (ATS 2026) - No abstract available

Immunology

Management of Progressive Pulmonary Fibroses - 2025 Update (PubMed, Dtsch Med Wochenschr) - "Recent advances in progressive pulmonary fibrosis treatment include three major developments: Nerandomilast, a selective PDE4B inhibitor, demonstrated significant reduction in FVC decline in Phase III trials for both IPF and PPF, with improved tolerability compared to current antifibrotics and expected EMA approval in 2026. Inhaled treprostinil received FDA approval in May 2025 as the first specific therapy for PH-ILD in the US, based on the INCREASE study showing improved exercise capacity, with ongoing TETON studies investigating its antifibrotic potential in IPF/PPF. Additionally, German guidelines propose expanded PPF progression criteria beyond international definitions to include more clinical parameters and prevent therapy exclusion of relevant patient groups. These developments mark the first potential new antifibrotic options in over a decade and promise multimodal treatment approaches combining systemic and inhaled therapies."

Journal • Review • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Rectus sheath block a retrospective review of a novel adjunct for treatment of the injection site pain associated with treprostinil subcutaneous infusion in pulmonary hypertension case series. (PubMed, Pain Manag) - "RSB may be a useful adjuvant on the initial days of treprostinil SC infusion. Given the small sample size and retrospective, within-patient observational design, these findings are exploratory and require confirmation in prospective controlled studies."

Journal • Retrospective data • Cardiovascular • Hypertension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Development of immune-derived molecular markers for coronary heart disease via multimachine learning. (PubMed, iScience) - "Furthermore, functional assays indicated that treprostinil significantly inhibited tumor necrosis factor-α-induced apoptosis in human umbilical vein endothelial cells, enhanced cell viability, and alleviated endothelial inflammatory responses. In conclusion, we established a robust CAD diagnostic model and screened potential therapeutic drugs, offering new perspectives for the diagnosis and treatment of CAD."

Biomarker • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Oncology • CD8 • TNFA

Real-World Dosing of Remodulin (Parenteral Treprostinil) in a Post-Sotatercept World (ATS 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Real-world use of theophylline in critically ill patients with sinus pauses: a case series. (PubMed, Front Cardiovasc Med) - "Patient A was a 74-year-old woman with a history of pulmonary arterial hypertension treated with subcutaneous treprostinil and a recent episode of catheter-associated Staphylococcus aureus bacteremia, for which she was receiving chronic suppressive doxycycline. These mechanisms enhance automaticity and reduce atrioventricular node refractoriness, augmenting sinus node automaticity and reducing the frequency and duration of sinus pauses. While these cases highlight the potential role of theophylline as a temporizing pacing strategy, additional research is needed to determine whether and how theophylline can be safely incorporated into treatment protocols for patients who are not suitable for device-based pacing."

Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Cerebral Palsy • CNS Disorders • Congestive Heart Failure • Critical care • Heart Failure • Hypertension • Infectious Disease • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Retrospective Observational Study of the Effects of Inhaled Treprostinil in ILD-PH Patients Over 12 Months (ATS 2026) - No abstract available

Observational data • Retrospective data • Interstitial Lung Disease

TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis (ATS 2026) - No abstract available

Clinical • Immunology • Pulmonary Disease • Respiratory Diseases

TETON-1 Phase 3 Clinical Trial of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis (ATS 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

TETON Phase 3 Clinical Trials of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis: Integrated Efficacy and Safety Results for TETON-1 and TETON-2 (ATS 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Severity Matters: Outcomes of Upfront Combination Therapy With Riociguat and Treprostinil in Advanced Pulmonary Arterial Hypertension (ATS 2026) - No abstract available

Combination therapy • Metastases • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases